Latest Healthcare News

Cochlear Limited has reported steady financial growth with a 4% rise in sales revenue and a 9% increase in underlying net profit for the fiscal year ending June 2025, maintaining its dividend payout.

TALi Digital Limited reported a sharp reduction in losses for FY25 alongside a strategic acquisition of YCDI Education Australia, signaling a pivot towards social-emotional learning. The company also secured nearly $1 million in fresh capital to support its growth ambitions.

Nyrada Inc has responded to ASX inquiries confirming the timely and compliant disclosure of positive safety data from its Phase I clinical trial of Xolatryp. The company detailed the timeline of its awareness and release of information, affirming adherence to continuous disclosure rules.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.30 per share for the fiscal year ending June 30, 2025, signaling steady returns for shareholders.

Pro Medicus Limited has delivered a record-breaking FY2025 with soaring profits and a wave of major US healthcare contracts, setting the stage for continued expansion.

Pro Medicus Limited has reported a robust FY25 with revenue climbing nearly 32% and net profit up 39%, prompting a significant dividend increase.

Argenica Therapeutics has received detailed FDA feedback outlining specific data requirements to lift the clinical hold on its ARG-007 stroke trial in the US, setting a clear path forward for its neuroprotective drug.

Tetratherix has landed a $3.3 million Australian Government grant to co-fund a $7.4 million project expanding its synthetic polymer production and supporting its US market entry in 2026.

Pacific Smiles Group has reported solid FY25 financial results, with patient fees rising 8.7% and underlying EBITDA up 12.1%, reflecting strong operational momentum.

Pacific Smiles Group Limited reported a sharp 75.5% drop in statutory profit for FY 2025 due to one-off takeover expenses, yet underlying profit surged 38.6% on solid revenue growth and operational improvements.

Anatara Lifesciences reported a 35% rise in net loss to $1.95 million for FY25, following pivotal Phase II trial results for its GaRP product that missed the primary efficacy endpoint but showed promising secondary benefits. The company is advancing commercialisation efforts and launching a new anti-obesity project amid tightened cash reserves.

Atomo Diagnostics has successfully placed $416,611.77 from its Share Purchase Plan shortfall, bolstered by a recent US order from Lumos Diagnostics. This capital injection strengthens Atomo’s position as it scales up production of its Pascal cassettes.